Preliminary results of RTOG 96-01 in progressive prostate cancer

RTOG 96-01 is a randomized, multi-center Phase III trial designed to compare bicalutamide monotherapy + salvage radiation therapy  to a placebo + salvage radiation alone in men with pT2-3N0Mo prostate cancer who have an elevated PSA after surgery. … READ MORE …

Sexual orientation and impact of androgen deprivation therapy

An article by a group of Romanian researchers published in October this year may have some controversial implications — so we want to be very clear that we don’t think too much should be read into it unless their data can be replicated by others. … READ MORE …

High-dose bicalutamide as second-line hormone therapy in CRPC patients

Historically there have been few really compelling data available to support the use of an additional or alternative antiandrogen as a second-line agent to extend either progression-free or overall survival of castration-resistant prostate cancer (CRPC) patients who progress after first-line hormone therapy (whether they have been treated by orchiectomy or medical castration with an LHRH agonist). … READ MORE …

Does ADT3 really work? The TARP study

A number of physicians and patients have believed for years that so-called “triple” androgen blockade (ADT3) is a more effective option than an LHRH alone or combined androgen deprivation in the treatment of men with advanced prostate cancer. However, the clinical evidence supporting this belief has been limited. … READ MORE …

Managing the side effects of bicalutamide monotherapy

In Europe, bicalutamide monotherapy with a dose of 150 mg/d is a widely used option for prostate cancer patients who wish to avoid the consequences of standard androgen deprivation using an LHRH agonist such as leuprolide acetate. However, bicalutamide induces gynecomastia (enlargement of the breasts) and mastalgia/mastodynia (pain in the breasts) in most patients. … READ MORE …

Generic bicalutamide now available in the USA

According to a report from the Associated Press, generic bicalutamide (the generic form of Casodex) is now available in the USA after approval by the US Food and Drug Administration. This offers a significant potential cost saving for many prostate cancer patients that they may want to take advantage of.

Prostate cancer news reports: Friday, May 8, 2009

In today’s news reports we address such issues as:

  • The possibility that type of initial treatment and comorbidities explain at least some racial disparities in prostate cancer survival
  • Failure of time to surgery to explain racial disparities in post-treatment outcome
  • Once-weekly bicalutamide as a regimen to prevent prostate cancer … READ MORE …